Bristol-Myers Squibb (BMS) Company has filed patent infringement case against Dr Reddy's Laboratories (DRL) over the cancer drug Ixempra.
In its petition filed in the United States District Court of New Jersey, BMS alleged that DRL has infringed the patents of its drug on three counts. According to the petition, DRL notified Bristol-Myers that the Indian drug major had submitted Abbreviated New Drug Application (ANDA) concerning its proposed drug product of Ixabepilone for injection, as required by the FDA rules. DRL's letter further notified that Ixabepilone injection patents are invalid and or will not be infringed by the commercial manufacture, use, offer for sale, or sale of DRL's ANDA product, the petition said. Ixempra, used in the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane (chemotherapy agents) has nearly $120 million sales, according to market reports.